-
Nelfinavir Mesylate in HIV and Ferroptosis
2026-09-21
Nelfinavir Mesylate combines a well-defined HIV-1 protease mechanism with an emerging use in DDI2–NFE2L1 and ferroptosis research. This guide translates its pharmacology into practical antiviral, proteostasis, and cell-death workflows with formulation, assay-design, and troubleshooting advice.
-
Licoricidin and PI3K/AKT Signaling in HCC
2026-09-21
A 2026 study investigated licoricidin, a prenylated isoflavone from Glycyrrhiza uralensis, as an inhibitor of hepatocellular carcinoma growth and metastasis. Using complementary cellular and animal models, the researchers associated its activity with apoptosis, S-phase arrest, epithelial–mesenchymal transition suppression, and reduced PI3K/AKT signaling.
-
Berbamine hydrochloride: NF-κB Activity Inhibitor
2026-09-19
Berbamine hydrochloride is a versatile pharmacological probe for connecting STAT3, calcium homeostasis, NF-κB signaling, and ferroptosis-related phenotypes. This workflow translates the METTL16-SENP3-LTF findings in hepatocellular carcinoma into practical dose-response, pathway, iron, and lipid-peroxidation assays.
-
B. fragilis, Vagal Cholinergic Signaling, and Seizures
2026-09-18
Jia et al. identify a gut–vagus–brain cholinergic circuit through which oral Bacteroides fragilis suppresses seizures in mice and shows efficacy in a randomized trial of pediatric refractory epilepsy. The study links colonic ChAT-positive cells, vagal transmission, and Lactobacillus colonization, providing a mechanistic framework for microbiota-targeted seizure research.
-
Human iPSC Intestinal Organoids for Pharmacokinetics
2026-09-18
Saito and colleagues developed a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be cryopreserved, expanded, and converted into two-dimensional intestinal epithelial monolayers containing metabolically and transport-competent enterocytes, creating a practical human model for oral drug pharmacokinetic studies.
-
Oligo (dT) 25 Beads for Immune-Cell RNA Workflows
2026-09-17
Oligo (dT) 25 Beads provide a selective, magnet-assisted route from total RNA or eukaryotic cells to polyadenylated mRNA for cDNA, RT-PCR, and sequencing workflows. This practical guide connects immune-aging research with sample-preparation decisions, including bead handling, direct cDNA synthesis, quality control, and troubleshooting.
-
NSC-23766: A Rac1 Assay Decision Framework
2026-09-17
NSC-23766 is a Rac GTPase inhibitor that links Rac1-GEF biology to interpretable cancer and cell-signaling assays. This evidence-based guide explains how to distinguish target engagement from downstream toxicity, using breast cancer combination data to improve experimental decisions.
-
Ambroxol Targets Nav1.8, TRPV1, and TRPA1
2026-09-16
A 2025 Journal of Pain study used whole-cell patch clamp recordings to define how ambroxol modulates human and rat Nav1.8, TRPV1, and TRPA1 channels. Its strongest mechanistic result was pronounced species dependence at Nav1.8, while additional TRPV1 and TRPA1 effects provide a plausible, but still preclinical, basis for topical neuropathic pain research.
-
Novobiocin Sodium: DNA Replication Workflows
2026-09-16
Novobiocin Sodium provides a practical way to separate bacterial DNA replication arrest from genomic DNA degradation while linking replication status to membrane growth and vacuole formation. This workflow translates a time-resolved Enterococcus faecalis protoplast study into reproducible microscopy, qPCR, washout, and antibiotic-resistance experiments.
-
Oridonin Protects Bone Through MAPK/NF-κB and BMP-2
2026-09-15
The reference study identifies oridonin as a dual-action candidate that suppresses thioacetamide-induced osteoclastogenesis while restoring osteoblast differentiation. Its mechanistic contribution is the connection of MAPK/NF-κB signaling in bone resorption with BMP-2/RUNX2 signaling in bone formation, providing a framework for studying therapies that address both sides of skeletal remodeling.
-
Telatinib: Mapping VEGF Signaling in TNBC
2026-09-15
Telatinib (BAY 57-9352) offers a multitarget framework for studying angiogenesis, invasion, and tumor-cell signaling in triple-negative breast cancer. This thought-leadership guide connects receptor-level pharmacology with phenotype-driven validation and translational decision-making.
-
Tetramethylrhodamine ethyl ester perchlorate assays
2026-09-14
Use TMRE to convert mitochondrial membrane-potential changes into actionable live-cell imaging and flow-cytometry data. This guide connects practical staining workflows with a new caspase-3/NDUFS1 mechanism implicated in trichothecene-induced liver injury, while highlighting controls and troubleshooting steps that prevent overinterpretation.
-
DiscoveryProbe™ Immunology Library: Assay Strategy
2026-09-14
The DiscoveryProbe Immunology/Inflammation Compound Library supports a decision-focused strategy for target validation, immune pathway profiling, and phenotypic screening. Learn how to combine its chemically diverse 295-compound set with multiplex PBMC measurements to distinguish genuine immunomodulation from cytotoxicity and assay artifacts.
-
TMEM16F Lipid Scrambling Shapes Ferroptosis Immunity
2026-09-13
Yang et al. identify TMEM16F-mediated plasma-membrane lipid scrambling as a late-stage suppressor of ferroptosis. Loss or inhibition of this process promotes membrane collapse, danger-signal release, tumor control, and stronger responses to PD-1 blockade, highlighting membrane mechanics as an immunologically relevant layer of ferroptosis biology.
-
Patient-Derived Gastric Cancer Assembloid Model
2026-09-12
Shapira-Netanelov and colleagues developed gastric cancer assembloids that combine patient-matched tumor organoids with tumor-derived stromal subpopulations. The model captures microenvironment-dependent gene expression and drug-response differences that are not apparent in organoid monocultures, strengthening its value for personalized cancer biology research.